Details

Autor(en) / Beteiligte

• Sheng, Chunquan
• Miao, Zhenyuan
• Zhang, Wannian

Titel

New strategies in the discovery of novel non-camptothecin topoisomerase I inhibitors

Ist Teil von

• Current medicinal chemistry, 2011-10, Vol.18 (28), p.4389-4409

Ort / Verlag

United Arab Emirates

Erscheinungsjahr

2011

Quelle

MEDLINE

Beschreibungen/Notizen

• Topoisomerase I (Top1) represents an important target of active interest in developing novel anticancer agents. Camptothecin derivatives are the only class of clinically approved Top1 inhibitors and show potent efficacy in anticancer therapy. However, there are also several major limitations for them, such as poor chemical stability, drug resistance, long infusions and side effects. To overcome the drawbacks of the camptothecins, the discovery of non-camptothecin Top1 inhibitors has recently emerged as a promising field to find better antitumor agents. Non-camptothecin Top1 inhibitors are expected to possess better chemical stability, different therapeutic activities and antitumor spectrum, improved pharmacokinetics and lower toxicity. This review focuses on various strategies that were used in the discovery of non-camptothecin Top1 inhibitors. In particular, the chemical scaffolds, structure-activity relationships and binding modes of the newly identified non-camptothecin Top1 inhibitors are discussed in detail.